Intelligence · Patent portfolio
Vertex Pharmaceuticals (Australia) Patents
Full USPTO pharma patent portfolio for Vertex Pharmaceuticals (Australia) — grant dates, expiration, and drug cross-links.
- Patents
- 991
- Expiring ≤24m
- 63
Quick answer
Vertex Pharmaceuticals (Australia) has 991 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 63 expire within 24 months — use filters for patent-cliff planning.
-
US 8431615
Dose forms
granted -
US 8426425
Aminopyrimidines useful as inhibitors of protein kinases
granted -
US 8426426
Gyrase inhibitors and uses thereof
granted -
US 8426359
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
granted -
US 8415387
Modulators of ATP-binding cassette transporters
granted -
US 8410132
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8410274
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8410112
Compounds useful as inhibitors of ATR kinase
granted -
US 8410133
Aminopyridines useful as inhibitors of protein kinases
granted -
US 8404849
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8404852
Gyrase inhibitors and uses thereof
granted -
US 8399458
Compounds useful as protein kinase inhibitors
granted -
US 8399479
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8399478
Thiophene-carboxamides useful as inhibitors of protein kinases
granted -
US 8399615
Processes and intermediates
granted -
US 8394952
Dihydrodiazepines useful as inhibitors of protein kinases
granted -
US 8394803
Gyrase inhibitors and uses thereof
granted -
US 8389734
Amides useful as inhibitors of voltage-gated sodium channels
granted -
US 8389727
Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide
granted -
US 8383633
Aminopyrimidines useful as kinase inhibitors
granted -
US 8383858
Processes and intermediates for preparing steric compounds
granted -
US 8377926
Aminopyridine kinase inhibitors
granted -
US 8378124
Preparation of protected alpha-keto beta-amino esters and amides
granted -
US 8372835
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
granted -
US 8372873
Inhibitors of serine proteases
granted -
US 8372850
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
granted -
US 8372846
Co-crystals and pharmaceutical compositions comprising the same
granted -
US 8372843
Quinolines useful as modulators of ION channels
granted -
US 8367697
Kinase inhibitors
granted -
US 8367690
Aminopyridine derivatives having aurora a selective inhibitory action
granted -
US 8367691
Modulators of muscarinic receptors
granted -
US 8367660
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8362032
Bicyclic derivatives as modulators of ion channels
granted -
US 8362253
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
granted -
US 8362043
Caspase inhibitors and uses thereof
granted -
US 8357718
Compounds and methods for the treatment or prevention of flavivirus infections
granted -
US 8357702
Bicyclic derivatives as modulators of voltage gated ion channels
granted -
US 8354419
Benzimidazole analogues for the treatment or prevention of flavivirus infections
granted -
US 8354427
Modulators of ATP-binding cassette transporters
granted -
US 8350077
Amides of creatine, method of their preparation, and remedy possessing a neuroprotective activity
granted -
US 8343980
Quinazoles useful as modulators of ion channels
granted -
US 8343998
Triazolothiadiazole inhibitor of c-Met protein kinase
granted -
US 8344147
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 8344153
Inhibitors of phosphatidylinositol 3-kinase
granted -
US 8343763
Heterocyclic derivatives as modulators of ion channels
granted -
US 8338412
Inhibitors of P38
granted -
US 8338597
Pyridones useful as inhibitors of kinases
granted -
US 8329924
Compounds and methods for the treatment or prevention of Flavivirus infections
granted
Frequently asked questions
How many patents does Vertex Pharmaceuticals (Australia) have?
991 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vertex Pharmaceuticals (Australia) patents expire?
63 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory